Neoplastic meningitis

Handbook of Clinical Neurology

Volumn 105, Issue , 2012, Pages 757-766

  Chamberlain, Marc C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855554296     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53502-3.00022-7     Document Type: Chapter

References (78)

1. Amer M.H., Al Sarraf M., Baker L.H., et al. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978, 42:660-668.
2. Balm M., Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 1996, 53:626-632.
3. Berweiler U., Krone A., Tonn J.C. Reservoir systems for intraventricular chemotherapy. J Neurooncol 1998, 38:141-143.
4. Biesterfeld S., Bernhard B., Bamborschke S., et al. DNA single cell cytometry in lymphocytic pleocytosis of the cerebrospinal fluid. Acta Neuropathol (Berl) 1993, 86:428-432.
5. Blaney S.M., Poplack D.G. New cytotoxic drugs for intrathecal administration. J Neurooncol 1998, 38:219-223.
6. Bleyer W.A., Drake J.C., Chabner B.A. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973, 289:770-773.
7. Bokstein F., Lossos A., Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 1998, 82:1756-1763.
8. Boogerd W., Vroom T.M., van Heerde P., et al. CSF cytology versus immunocytochemistry in meningeal carcinomatosis. J Neurol Neurosurg Psychiatry 1988, 51:142-145.
9. Boogerd W., Dorresteijn L.D.A., van der Sande J.J., et al. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000, 55:117-119.
10. Boyle R., Thomas M., Adams J.H. Diffuse involvement of the leptomeninges by tumour - a clinical and pathological study of 63 cases. Postgrad Med J 1980, 56:149-158.
11. Chamberlain M.C. Comparative spine imaging in leptomeningeal metastases. J Neurooncol 1995, 23:233-238.
12. Chamberlain M.C. Carcinomatous meningitis. Arch Neurol 1997, 54:16-17.
13. Chamberlain M.C. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology 1998, 50:1173-1175.
14. Chamberlain M.C. Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol 1998, 38:135-140.
15. Chamberlain M.C. Neoplastic meningitis-related encephalopathy: prognostic significance. Neurology 2003, 60:A17-A18.
16. 111 indium-DTPA CSF flow studies. Neurology 1991, 41:1765-1769.
17. 111 indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 1996, 46:1674-1677.
18. Chamberlain M.C., Kormanik P.A. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol 1997, 54:1364-1368.
19. Chamberlain M.C., Kormanik P.A. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 1997, 35:55-64.
20. Chamberlain M.C., Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 1998, 55:506-512.
21. Chamberlain M.C., Sandy A.D., Press G.A. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990, 40:435-438.
22. Chamberlain M.C., Kormanik P.A., Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997, 87:694-699.
23. 111 Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1999, 52:216-217.
24. Chamberlain M.C., Kormanik P.A., Glantz M.J. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neurooncol 2001, 3:42-45.
25. Cheng T.M., O'Neill B.P., Scheithauer B.W., et al. Chronic meningitis: the role of meningeal or cortical biopsy. Neurosurgery 1994, 34:590-595.
26. Cibas E.S., Malkin M.G., Posner J.B., et al. Detection of DNA abnormalities by flow cytometry in cells from cerebrospinal fluid. Am J Clin Pathol 1987, 88:570-577.
27. 131 I-radiolabelled monoclonal antibodies. J Neurooncol 1998, 38:225-232.
28. DeAngelis L.M. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998, 38:245-252.
29. Freilich R.J., Krol G., DeAngelis L.M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995, 38:51-57.
30. Garson J.A., Coakham H.B., Kemshead J.T., et al. The role of monoclonal antibodies in brain tumour diagnosis and cerebrospinal fluid (CSF) cytology. J Neurooncol 1985, 3:165-171.
31. Giannone L., Greco F.A., Hainsworth J.D. Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 1986, 4:68-73.
32. Glantz M.J., Hall W.A., Cole B.F., et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995, 75:2919-2931.
33. Glantz M.J., Cole B.F., Glantz L.K., et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998, 82:733-739.
34. Glantz M.J., Cole B.F., Recht L., et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?. J Clin Oncol 1998, 16:1561-1567.
35. Glantz M.J., Jaeckle K.A., Chamberlain M.C., et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (depocyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999, 5:3394-3402.
36. Glantz M.J., LaFollette S., Jaeckle K.A., et al. Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999, 17:3110-3116.
37. Glass J.P., Melamed M., Chernik N.L., et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979, 29:1369-1375.
38. Gonzalez-Vitale J.C., Garcia-Bunuel R. Meningeal carcinomatosis. Cancer 1976, 37:2906-2911.
39. Grossman S.A., Krabak M.J. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999, 25:103-119.
40. Herrlinger U., Weller M., Schabet M. New aspects of immunotherapy of leptomeningeal metastasis. J Neurooncol 1998, 38:233-239.
41. Hildebrand J. Prophylaxis and treatment of leptomeningeal carcinomatosis in solid tumors of adulthood. J Neurooncol 1998, 38:193-198.
42. Hitchins R.N., Bell D.R., Woods R.L., et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987, 5:1655-1662.
43. Hovestadt A., Henzen-Logmans S.C., Vecht C.J. Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitis. Br J Cancer 1990, 62:653-654.
44. Kaplan J.G., DeSouza T.G., Farkash A., et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990, 9:225-229.
45. Kerr J.Z., Berg S., Blaney S.M. Intrathecal chemotherapy. Crypt Rev Oncol Hematol 2001, 37:227-236.
46. Klee G.G., Tallman R.D., Goellner J.R., et al. Elevation of carcinoembryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosis. Mayo Clin Proc 1986, 61:9-13.
47. Kolmel H.W. Cytology of neoplastic meningosis. J Neurooncol 1998, 38:121-125.
48. Little J.R., Dale A.J., Okazaki H. Meningeal carcinomatosis. Clinical manifestations. Arch Neurol 1974, 30:138-143.
49. 111 Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1998, 50:438-444.
50. Mittl R.L., Yousem D.M. Frequency of unexplained meningeal enhancement in the brain after lumbar puncture. AJNR Am J Neuroradiol 1994, 15:633-638.
51. Murray J.J., Greco F.A., Wolff S.N., et al. Neoplastic meningitis. Marked variations of cerebrospinal fluid composition in the absence of extradural block. Am J Med 1983, 75:289-294.
52. Nugent J.L., Bunn P.A., Matthews M.J., et al. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer 1979, 44:1885-1893.
53. Rhodes C.H., Glantz M.J., Glantz L., et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 1996, 77:543-548.
54. Rogers L.R., Duchesneau P.M., Nunez C., et al. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology 1992, 42:1239-1241.
55. Rosen S.T., Aisner J., Makuch R.W., et al. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine (Baltimore) 1982, 61:45-53.
56. Sampson J.H., Archer G.E., Villavicencio A.T., et al. Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res 1999, 5:1183-1188.
57. Sandberg D.I., Bilsky M.H., Souweidane M.M., et al. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 2000, 47:49-54.
58. Sause W.T., Crowley J., Eyre H.J., et al. Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases - a Southwest Oncology Group study. J Neurooncol 1998, 6:107-112.
59. Schuknecht B., Huber P., Buller B., et al. Spinal leptomeningeal neoplastic disease. Evaluation by MR, myelography and CT myelography. Eur Neurol 1992, 32:11-16.
60. Shapiro W.R., Young D.F., Mehta B.M. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975, 293:161-166.
61. Shapiro W.R., Posner J.B., Ushio Y., et al. Treatment of meningeal neoplasms. Cancer Treat Rep 1977, 61:733-743.
62. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?. J Neurooncol 1998, 38:151-157.
63. Siegal T., Pfeffer M.R., Steiner I. Antibiotic therapy for infected Ommaya reservoir systems. Neurosurgery 1988, 22:97-100.
64. Siegal T., Lossos A., Pfeffer M.R. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994, 44:1463-1469.
65. Sorensen S.C., Eagan R.T., Scott M. Meningeal carcinomatosis in patients with primary breast or lung cancer. Mayo Clin Proc 1984, 59:91-94.
66. Stockhammer G., Poewe W., Burgstaller S., et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 2000, 54:1670-1676.
67. Sze G., Soletsky S., Bronen R., et al. MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. AJR Am J Roentgenol 1989, 153:1039-1049.
68. Trump D.L., Grossman S.A., Thompson G., et al. CSF infections complicating the management of neoplastic meningitis. Clinical features and results of therapy. Arch Intern Med 1982, 142:583-586.
69. Twijnstra A., van Zanten A.P., Hart A.A., et al. Serial lumbar and ventricle cerebrospinal fluid lactate dehydrogenase activities in patients with leptomeningeal metastases from solid and haematological tumours. J Neurol Neurosurg Psychiatry 1987, 50:313-320.
70. Twijnstra A., Ongerboer de Visser B.W., van Zanten A.P., et al. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J Neurooncol 1989, 7:57-63.
71. van Oostenbrugge R.J., Hopman A.H., Arends J.W., et al. The value of interphase cytogenetics in cytology for the diagnosis of leptomeningeal metastases. Neurology 1998, 51:906-908.
72. van Oostenbrugge R.J., Hopman A.H., Ramaekers F.C., et al. In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis. J Neurooncol 1998, 38:127-133.
73. van Oostenbrugge R.J., Twijnstra A. Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology 1999, 53:382-385.
74. van Zanten A.P., Twijnstra A., Hart A.A., et al. Cerebrospinal fluid lactate dehydrogenase activities in patients with central nervous system metastases. Clin Chim Acta 1986, 161:259-268.
75. Vrionis F.D. Gene therapy of neoplastic meningiosis. J Neurooncol 1998, 38:241-244.
76. Wasserstrom W.R., Schwartz M.K., Fleisher M., et al. Cerebrospinal fluid biochemical markers in central nervous system tumors: a review. Ann Clin Lab Sci 1981, 11:239-251.
77. Wasserstrom W.R., Glass J.P., Posner J.B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982, 49:759-772.
78. Yap H.Y., Yap B.S., Tashima C.K., et al. Meningeal carcinomatosis in breast cancer. Cancer 1978, 42:283-286.